BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 23331006)

  • 1. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.
    Poruk KE; Gay DZ; Brown K; Mulvihill JD; Boucher KM; Scaife CL; Firpo MA; Mulvihill SJ
    Curr Mol Med; 2013 Mar; 13(3):340-51. PubMed ID: 23331006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice.
    Duraker N; Hot S; Polat Y; Höbek A; Gençler N; Urhan N
    J Surg Oncol; 2007 Feb; 95(2):142-7. PubMed ID: 17262731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients.
    Kanda M; Fujii T; Takami H; Suenaga M; Inokawa Y; Yamada S; Nakayama G; Sugimoto H; Koike M; Nomoto S; Kodera Y
    Surg Today; 2014 Sep; 44(9):1692-701. PubMed ID: 24114022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
    Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
    PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer].
    Kokhanenko NIu; Ignashov AM; Varga EV; Polkanova MS; Aleshina LA; Kimbarovskaia AA; Osipenko SK; Lebedev EG
    Vopr Onkol; 2001; 47(3):294-7. PubMed ID: 11544826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
    Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
    Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
    Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
    Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma.
    Nazli O; Bozdag AD; Tansug T; Kir R; Kaymak E
    Hepatogastroenterology; 2000; 47(36):1750-2. PubMed ID: 11149048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions.
    Cerwenka H; Aigner R; Bacher H; Werkgartner G; el-Shabrawi A; Quehenberger F; Mischinger HJ
    Anticancer Res; 1999; 19(1B):849-51. PubMed ID: 10216504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
    Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
    Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer.
    Ychou M; Duffour J; Kramar A; Gourgou S; Grenier J
    Dis Markers; 2000; 16(3-4):105-10. PubMed ID: 11381189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic and prognostic values of CA 19-9 and CEA in periampullary cancers.
    Kau SY; Shyr YM; Su CH; Wu CW; Lui WY
    J Am Coll Surg; 1999 Apr; 188(4):415-20. PubMed ID: 10195726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TPS, CA 19-9, VEGF-A, and CEA as diagnostic and prognostic factors in patients with mass lesions in the pancreatic head.
    Sandblom G; Granroth S; Rasmussen IC
    Ups J Med Sci; 2008; 113(1):57-64. PubMed ID: 18521799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.
    Haas M; Laubender RP; Stieber P; Holdenrieder S; Bruns CJ; Wilkowski R; Mansmann U; Heinemann V; Boeck S
    Tumour Biol; 2010 Aug; 31(4):351-7. PubMed ID: 20480409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
    Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
    J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H; Kaya M; Cengiz A
    Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bile levels of carcino-embryonic antigen in patients with hepatopancreatobiliary disease.
    Buffet C; Fourré C; Altman C; Prat F; Fritsch J; Choury A; Briantais MJ; Desgrez A; Etienne JP
    Eur J Gastroenterol Hepatol; 1996 Feb; 8(2):131-4. PubMed ID: 8723416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.